CBL-0137 FREE BASE
Diffuse Midline Glioma, H3 K27-Altered
Children's Oncology GroupSmall moleculePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Diffuse Midline Glioma, H3 K27-Altered cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid University of Göttingen | Phase 3 | B |
Cetuximab University of Miami | Phase 1/2 | CCC |
h3k27m peptide vaccine German Cancer Research Center | Phase 1 | CC |
Imiquimod German Cancer Research Center | Phase 1 | CC |
Atezolizumab German Cancer Research Center | Phase 1 | CC |
VIPIVOTIDE TETRAXETAN Memorial Sloan Kettering Cancer Center | Phase 1 | CC |
Lorlatinib Nationwide Children's Hospital | Early Phase 1 | C |
azd1390 Children's Oncology Group | Phase 1 | NR |
Same molecule, other indications
CBL-0137 FREE BASE is also rated in:
Metastatic Malignant Neoplasm in the Central Nervous SystemDormant
CC
Indicative ·
44 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →